Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | KDM5A | P29375 | 2/20 | 0.38 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.38 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.38 |
| ▸ | CEL | P19835 | 2/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
| ▸ | KDM4A | O75164 | 1/20 | 0.38 |
| ▸ | METAP1 | P53582 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2533487 | 1.00 | CYP1A2 (0.56) | CYP1A2SIGMAR1EPHX1HPGDKDM5A | |
| SCHEMBL1240653 | 1.00 | CYP1A2 (0.56) | CYP1A2SIGMAR1EPHX1HPGDKDM5A | |
| SCHEMBL473577 | 0.97 | — | — | |
| SCHEMBL2078510 | 0.92 | SIGMAR1 (0.56) | CYP1A2SIGMAR1EPHX1HPGDKDM5A | |
| SCHEMBL5313489 | 0.92 | SIGMAR1 (0.56) | CYP1A2SIGMAR1EPHX1HPGDKDM5A | |
| SCHEMBL329924 | 0.92 | SIGMAR1 (0.56) | CYP1A2SIGMAR1EPHX1HPGDKDM5A | |
| SCHEMBL473467 | 0.92 | — | — | |
| SCHEMBL1009023 | 0.90 | SIGMAR1 (0.60) | CYP1A2SIGMAR1EPHX1KDM5APHF8 | |
| SCHEMBL1007121 | 0.90 | SIGMAR1 (0.60) | CYP1A2SIGMAR1EPHX1KDM5APHF8 | |
| SCHEMBL1008867 | 0.90 | SIGMAR1 (0.60) | CYP1A2SIGMAR1EPHX1KDM5APHF8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 263 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111217821-B | Preparation method of series dioxane quinazoline derivatives | 北京工业大学 | 2021-04-23 | — | — | CN | claimed |
| CN-111217821-A | Preparation method of series dioxane quinazoline derivatives | 北京工业大学 | 2020-06-02 | — | — | CN | claimed |
| US-8461135-B2 | Boron-containing small molecules as anti-inflammatory agents | ANACOR PHARMACEUTICALS, INC. (US) | 2013-06-11 | — | — | US | claimed |
| US-8039450-B2 | Boron-containing small molecules as anti-inflammatory agents | ANACOR PHARMACEUTICALS, INC. (US) | 2011-10-18 | — | — | US | claimed |
| US-7884210-B2 | {2-[3-(2-Cyclohex-1-enyl-ethyl)-3-(trans-4-methyl-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid; for treatment of type 2 diabetes | NOVO NORDISK A/S (DK) | 2011-02-08 | — | — | US | claimed |
| US-20090105482-A1 | Urea Glucokinase Activators | NOVO NORDISK A/S (DK) | 2009-04-23 | — | — | US | claimed |
| JP-2009501198-A | — | — | 2009-01-15 | — | — | JP | claimed |
| EP-1904467-A1 | UREA GLUCOKINASE ACTIVATORS | Novo Nordisk A/S (DK) | 2008-04-02 | — | — | EP | claimed |
| WO-2007006814-A1 | UREA GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2007-01-18 | — | — | WO | claimed |
| EP-0443560-A2 | HIV protease inhibitors | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1991-08-28 | — | — | EP | claimed |
| EP-0443573-A2 | HIV protease inhibitors containing derived amino acids | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1991-08-28 | — | — | EP | claimed |
| CN-112279864-B | Difunctional coumarin oxime ester compound and preparation and application thereof | 湖北固润科技股份有限公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-117986253-A | Blue light red phase pigment and preparation method thereof | 先尼科化工（上海）有限公司 | 2024-05-07 | — | — | CN | disclosed |
| CN-115504896-B | Acrylic formate compound for LED photopolymerization, preparation method and application thereof | 湖北固润科技股份有限公司 | 2024-05-07 | — | — | CN | disclosed |
| WO-2024078413-A1 | ACRYLOYL FORMATE COMPOUND FOR LED PHOTOPOLYMERIZATION, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 湖北固润科技股份有限公司 | 2024-04-18 | — | — | WO | disclosed |
| US-4192944-A | ANTIANAPHYLACTIC | BRISTOL-MYERS COMPANY (US) | 1980-03-11 | — | — | US | disclosed |
| US-4122274-A | ANTIALLERGY | BRISTOL-MYERS COMPANY (US) | 1978-10-24 | — | — | US | disclosed |
| US-4082751-A | ANTIALLERGENS | BRISTOL-MYERS COMPANY (US) | 1978-04-04 | — | — | US | disclosed |
| US-4031093-A | ANTIALLERGENS | BRISTOL-MYERS COMPANY (US) | 1977-06-21 | — | — | US | disclosed |
| US-3936479-A | 2-BENZAMIDO-BENZOPHENONES, UV STABILIZERS, PLASTICS | SANDOZ LTD., (SANDOZ AG) (CH) | 1976-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105482-A1 | Urea Glucokinase Activators | GCK, GCKR, HK2 | CYP1A2 1207/4885SIGMAR1 4399/4885EPHX1 4138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.